Reports

Drug name	NICE TAs	Comments
Aflibercept (Eylea®) injection	TA305 - Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion TA346 - Aflibercept for treating diabetic macular oedema TA294 - Aflibercept solution for injection for treating wet age-related macular degeneration TA409 - Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion TA486 - Aflibercept for treating choroidal neovascularisation
Alemtuzumab concentrate for infusion	TA312 - Alemtuzumab for treating relapsing-remitting multiple sclerosis	Hospital use only
Alirocumab (Praluent®)	TA393 - Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia	To be used in line with NICE TA
Alitretinoin 30mg capsules	TA177 - Alitretinoin for the treatment of severe chronic hand eczema
Alpelisib	TA816: Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer
Alteplase injection	TA52 - Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction	Hospital use only
Anakinra (Kineret®)	TA685 - Anakinra for treating Still’s disease
Anastrozole tablets	TA112 - Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
Andexanet alfa (Ondexxya®)	TA697 - Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban
Apalutamide	TA741 - Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports